| scholarly article | Q13442814 |
| P2093 | author name string | Mamdouh M El-Shishtawy | |
| Tarek M Abbas | |||
| Mokhtar M Mabrouk | |||
| Mohammed A Sobh | |||
| Gehad A El-Nakib | |||
| Tarek M Mostafa | |||
| P2860 | cites work | Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential | Q24658099 |
| Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis | Q28290519 | ||
| Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis | Q34301089 | ||
| Electrolyzed-reduced water reduced hemodialysis-induced erythrocyte impairment in end-stage renal disease patients | Q34535945 | ||
| Asymmetric dimethylarginine correlates with measures of disease severity, major adverse cardiovascular events and all-cause mortality in patients with peripheral arterial disease. | Q35090446 | ||
| Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure | Q35810410 | ||
| Antioxidative effects of erythropoietin | Q36974225 | ||
| Alpha-lipoic acid supplementation and diabetes | Q37329377 | ||
| Nonrenal regulation of EPO synthesis | Q37375988 | ||
| What is causing the mortality in treating the anemia of chronic kidney disease: erythropoietin dose or hemoglobin level? | Q37778263 | ||
| Alpha-lipoic acid activates dimethylarginine dimethylaminohydrolase in cultured endothelial cells. | Q39684245 | ||
| Oxidative damage to RBC membranes and pentose phosphate shunt activity in hemodialysis patients after suspension of erythropoietin treatment. | Q42513782 | ||
| Asymmetrical dimethylarginine is associated with renal and cardiovascular outcomes and all-cause mortality in renal transplant recipients | Q42637253 | ||
| Abrogation of cisplatin-induced nephrotoxicity in mice by alpha lipoic acid through ameliorating oxidative stress and enhancing gene expression of antioxidant enzymes | Q42730565 | ||
| Protective effects of irbesartan and alpha lipoic acid in STZ-induced diabetic nephropathy in rats | Q43072127 | ||
| Alpha-lipoic acid improves vascular endothelial function in patients with type 2 diabetes: a placebo-controlled randomized trial | Q43202055 | ||
| Treatment with alpha-lipoic acid reduces asymmetric dimethylarginine in patients with type 2 diabetes mellitus | Q43224678 | ||
| How can erythropoietin requirements be reduced in dialysis patients? | Q43339036 | ||
| Effect of alpha-lipoic acid on the progression of endothelial cell damage and albuminuria in patients with diabetes mellitus: an exploratory study | Q43588803 | ||
| Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. | Q43850038 | ||
| Effects of vitamin C infusion and vitamin E-coated membrane on hemodialysis-induced oxidative stress | Q45165519 | ||
| Chronic hepatitis ameliorates anaemia in haemodialysis patients | Q45350035 | ||
| Antioxidant therapy does not ameliorate oxidative stress and inflammation in patients with end-stage renal disease. | Q46035400 | ||
| Factors that condition the response to erythropoietin in patients on hemodialysis and their relation to mortality | Q46228211 | ||
| Mechanisms of antioxidant and pro-oxidant effects of alpha-lipoic acid in the diabetic and nondiabetic kidney | Q46393330 | ||
| Coenzyme Q10 administration suppresses both oxidative and antioxidative markers in hemodialysis patients | Q46570325 | ||
| Effects of erythropoietin on left ventricular hypertrophy in adults with severe chronic renal failure and hemoglobin <10 g/dL. | Q46598179 | ||
| Efficacy and safety of oral versus intravenous ascorbic acid for anaemia in haemodialysis patients | Q46657532 | ||
| Long-term use of vitamin E-coated polysulfone membrane reduces oxidative stress markers in haemodialysis patients | Q46749958 | ||
| Alpha-lipoic acid protects against renal ischaemia-reperfusion injury in rats | Q46946118 | ||
| Erythrocyte antioxidant defense system in patients with chronic renal failure according to the hemodialysis conditions | Q46972854 | ||
| Alpha-lipoic acid preserves the structural and functional integrity of red blood cells by adjusting the redox disturbance and decreasing O-GlcNAc modifications of antioxidant enzymes and heat shock proteins in diabetic rats. | Q50522532 | ||
| α-lipoic acid can improve endothelial dysfunction in subjects with impaired fasting glucose. | Q51381181 | ||
| A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. | Q53399563 | ||
| Effects of alpha-lipoic acid on the plasma levels of asymmetric dimethylarginine in diabetic end-stage renal disease patients on hemodialysis: a pilot study. | Q53579779 | ||
| Effect of erythropoietin on cardiovascular prognosis parameters in hemodialysis patients. | Q53891354 | ||
| Associations between Changes in Hemoglobin and Administered Erythropoiesis-Stimulating Agent and Survival in Hemodialysis Patients | Q57772131 | ||
| Influence of Oral Vitamin E Therapy on Micro-Inflammation and Cardiovascular Disease Markers in Chronic Hemodialysis Patients | Q57825359 | ||
| Determination of aldehydic lipid peroxidation products: malonaldehyde and 4-hydroxynonenal | Q68592280 | ||
| Reduced glutathione for the treatment of anemia during hemodialysis: a preliminary communication | Q70920973 | ||
| The role of the oxidative state of glutathione and glutathione-related enzymes in anemia of hemodialysis patients | Q71823985 | ||
| Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial | Q73176018 | ||
| Alpha-lipoic acid. Monograph | Q79541602 | ||
| Essential role of endothelial nitric oxide synthase in vascular effects of erythropoietin | Q79985201 | ||
| Effect of hepatitis C infection on anemia in hemodialysis patients | Q80692233 | ||
| Anemia and mortality in hemodialysis patients: accounting for morbidity and treatment variables updated over time | Q81343836 | ||
| KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease | Q83296275 | ||
| High concentrations of asymmetric dimethylarginine are associated with ST-segment resolution failure after reperfusion for acute myocardial infarction | Q83504155 | ||
| N-acetylcysteine for the management of anemia and oxidative stress in hemodialysis patients | Q84532629 | ||
| Effects of alpha-lipoic acid supplementation on inflammation, oxidative stress, and serum lipid profile levels in patients with end-stage renal disease on hemodialysis | Q84931385 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 161-168 | |
| P577 | publication date | 2013-08-27 | |
| P1433 | published in | International Journal of Nephrology and Renovascular Disease | Q6051506 |
| P1476 | title | Role of alpha-lipoic acid in the management of anemia in patients with chronic renal failure undergoing hemodialysis | |
| P478 | volume | 6 |
| Q93106871 | Alpha lipoic acid supplementation improved antioxidant enzyme activities in hemodialysis patients |
| Q61817225 | Antioxidant Supplementation in Renal Replacement Therapy Patients: Is There Evidence? |
| Q51736055 | Efficacy of Nutritional Interventions on Inflammatory Markers in Haemodialysis Patients: A Systematic Review and Limited Meta-Analysis. |
| Q42022548 | THE COMBINATION OF α-LIPOIC ACID INTAKE WITH ECCENTRIC EXERCISE MODULATES ERYTHROPOIETIN RELEASE. |
| Q55183262 | The effects of alpha-lipoic acid supplementation on inflammatory markers among patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials. |
Search more.